Reference priceEUR €577.50Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Retacrit |
|---|---|
| Manufacturer | Pfizer Pharma GmbH |
| Prescription required | Yes |
Retacrit 40000Units/ml injection,4vial x 2ml (epoetin alfa-epbx)
epoetin alfa-epbx
Description
Retacrit 40000Units/ml injection,4vial x 2ml (epoetin alfa-epbx) is a medicine catalog record in the MediPriceHub database. Active ingredient: epoetin alfa-epbx. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Pfizer Pharma GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Chemotherapy drugs. Pack information: 40000, 4 x 2. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
RETACRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Limitations of Use RETACRIT has not been shown to improve quality of life, fatigue, or patient well-being . RETACRIT is not indicated for use: • Treatment of anemia due to o Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis . o Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection . o The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy . o Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis . o Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection . o The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy . • Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery . • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy . • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure . • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion . • In patients scheduled for surgery who are willing to donate autologous blood . • In patients undergoing cardiac or vascular surgery . • As a substitute for RBC transfusions in patients who require immediate correction of anemia .How to Use
Use epoetin alfa-epbx under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: epoetin alfa-epbx. Pack size: 40000, 4 x 2. Pack unit: box. Manufacturer: Pfizer Pharma GmbH. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Chemotherapy drugs. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Esta información es solo orientativa. Consulta a un profesional sanitario antes de usar cualquier medicamento.